Analysis of cytokines in tear fluid from atopic dermatitis patients with dupilumab-associated ocular adverse events

被引：3

作者：

Vuillemey, L. ^{[1
]}

Febvay, C. ^{[1
]}

Puzenat, E. ^{[2
]}

Bellanger, A. P. ^{[3
]}

Chague, C. ^{[4
]}

Puyraveau, M. ^{[5
]}

Delbosc, B. ^{[1
,4
]}

Gauthier, A. -S. ^{[1
,4
]}

Aubin, F. ^{[2
,4
]}

机构：

[1] CHU Besancon, Dept Ophthalmol, Besancon, France

[2] CHU Besancon, Dept Dermatol, Besancon, France

[3] CHU Besancon, Dept Parasitol, Besancon, France

[4] Univ Bourgogne Franche Comte, Federat Hosp Univ INCREASE, Interact Hote Greffon Tumeur Ingn Cellulaire & Ge, LabEx LipSTIC,INSERM,UMR1098,EFS BFC, Besancon, France

[5] CHU Besancon, Dept Clin Res, Besancon, France

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 36卷 / 03期

关键词：

VERNAL KERATOCONJUNCTIVITIS; DISEASE;

D O I：

10.1111/jdv.17729

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：E195 / E197

页数：3

共 50 条

[31] Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients
Achten, Roselie
Thijs, Judith
van Luijk, Chantal
Knol, Edward
Delemarre, Eveline
de Graaf, Marlies
Bakker, Daphne
de Boer, Joke
van Wijk, Femke
de Bruin-Weller, Marjolein
CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (02): : 239 - 243
[32] Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study
Beyrouti, Alexandre
Deuze, Juliette
Fontas, Eric
Foureau, Aurore
Barbarot, Sebastien
Aubert, Helene
Bernier, Claire
Le Moigne, Marie
Passeron, Thierry
Boukari, Feriel
Garnier, Margaux
Jachiet, Marie
Tetart, Florence
Seneschal, Julien
Toussaiant, Clementine
Mah, Emmanuel
Leleu, Camille
Regnault, Marie Masson
Pasteur, Justine
Nosbaum, Audrey
Badaoui, Antoine
Fougerousse, Anne-Claire
Pralong, Pauline
Viguier, Manuelle
Droitcourt, Catherine
Abasq, Claire
Mallet, Phanie
Mallet, Stephaine
Raison-Peyron, Nadia
Staumont-Sall, Delphine
Hubiche, Thomas
Grp Recherche Atopique GREAT Res Grp
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2025, 13 (02): : 353 - 360
[33] Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients
Costedoat, Ingrid
Wallaert, Martin
Gaultier, Aurelie
Vasseur, Robin
Vanhaecke, Clelia
Viguier, Manuelle
Cordelette, Charles
Denoyer, Alexandre
le Bouedec, Marie-Christine Ferrier
Coutu, Adrien
Lamiaux, Marie
Tran, Thi Ha Chau
Lacour, Jean Philippe
Elmaleh, Valerie
Tetart, Florence
Gueudry, Julie
Tauber, Marie
Giordano-Labadie, Francoise
Cassagne, Myriam
Nosbaum, Audrey
Ouilhon, Coralie
Jachiet, Marie
Tadayoni, Ramin
Dezoteux, Frederic
Staumont-Salle, Delphine
Bouleau, Julien
Labalette, Pierre
Doan, Serge
Soria, Angele
Mortemousque, Bruno
Seneschal, Julien
Barbarot, Sebastien
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (05) : 1056 - 1063
[34] MULTICENTRE PROSPECTIVE OBSERVATIONAL STUDY OF DUPILUMAB-INDUCED OCULAR EVENTS IN ATOPIC DERMATITIS PATIENTS
Costedoat, Ingrid
Wallaert, Martin
Gaultier, Aurelie
Vasseur, Robin
Vanhaecke, Clelia
Viguier, Manuelle
Cordelette, Charles
Denoyer, Alexandre
le Bouedec, Marie-Christine Ferrier
Coutu, Adrien
Lamiaux, Marie
Thi Ha Chau Tran
Lacour, Jean-Philippe
Elmaleh, Valerie
Tetart, Florence
Gueudry, Julie
Tauber, Marie
Giordano-Labadie, Francoise
Cassagne, Myriam
Nosbaum, Audrey
Ouilhon, Coralie
Jachiet, Marie
Tadayoni, Ramin
Dezoteux, Frederic
Staumont-Salle, Delphine
Bouleau, Julien
Labalette, Pierre
Doan, Serge
Soria, Angele
Mortemousque, Bruno
Seneschal, Julien
Barbarot, Sebastien
ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 32 - 33
[35] Dupilumab in patients with atopic dermatitis: risk of ocular surface disease
Reactions Weekly, 2023, 1981 (1) : 8 - 8
[36] Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis
Ou, Zuzhen
Chen, Chao
Chen, Aijun
Yang, Yao
Zhou, Weikang
INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 54 : 303 - 310
[37] Evolution of dupilumab-associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO-ADOC study)
Reguiai, Ziad
Becherel, Pierre Andre
Perrot, Jean Luc
Boulard, Claire
Fougerousse, Anne Claire
Begon, Edouard
Badaoui, Antoine
Poreaux, Claire
Parier, Josiane
Liegeon, Anne-Laure
Levavasseur, Matthieu
Bing, Anne-Claire
Esteve, Eric
Maccari, Francois
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (11) : 2149 - 2155
[38] Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related?
Mastorino, Luca
Ortoncelli, Michela
Avallone, Gianluca
Quaglino, Pietro
Ribero, Simone
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (10) : E370 - E372
[39] Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis
Patruno, Cataldo
Potestio, Luca
Fabbrocini, Gabriella
Napolitano, Maddalena
DERMATOLOGIC THERAPY, 2022, 35 (12)
[40] Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review
Neagu, N.
Dianzani, C.
Avallone, G.
Dell'Aquila, C.
Morariu, S. H.
Zalaudek, I
Conforti, C.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (06) : 820 - 835

← 1 2 3 4 5 →